[Form 4] Zivo Bioscience, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Laith Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), reported a purchase of 15,322 shares of the company's common stock on 09/30/2025 at a price of $15.99 per share. After the transaction, the filing shows beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC. The Form 4 was signed on 10/02/2025.

This report documents an insider acquisition, increasing the reporting person's indirect stake via an investment vehicle. The filing does not disclose any derivative transactions or additional context for the purchase beyond the amounts, price, and ownership form.

Positive

• Director and 10% owner increased stake by 15,322 shares
• Purchase reported at a clear per-share price of $15.99
• Beneficial ownership after transaction is explicitly stated as 573,436 shares held indirectly via HEP Investments LLC

Negative

• Filing provides no explanation for the purpose of the purchase
• Transaction is held indirectly, which offers less transparency about direct personal ownership

Insights

Insider Transactions Analyst

Insider bought 15,322 ZIVO shares at $15.99, raising indirect holdings to 573,436 shares.

The purchase by a director and 10% owner is a direct disclosure of an insider acquisition on 09/30/2025. Because the shares are held indirectly through HEP Investments LLC, this filing clarifies beneficial ownership rather than a personal brokerage trade.

This is a material Form 4 disclosure because it shows a change in insider ownership levels; the filing contains no derivatives, sale activity, or additional terms to indicate further structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

YALDOO LAITH L

(Last) (First) (Middle)

2125 BUTTERFIELD ROAD, SUITE 100

(Street)

TROY MI 48084

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ zivo ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		P		15,322	A	$15.99	573,436	I	by HEP Investments LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Laith Yaldoo	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZIVO director Laith Yaldoo report?

He reported acquiring 15,322 shares of ZIVO common stock on 09/30/2025 at $15.99 per share.

How many ZIVO shares does Laith Yaldoo beneficially own after the transaction?

The Form 4 states beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC.

What is Laith Yaldoo's relationship to ZIVO?

The filing identifies him as a director and a 10% owner of the company.

Were any derivative securities reported in this Form 4 for ZIVO?

No. Table II for derivative securities contains no reported transactions in this filing.

When was the Form 4 signed?

The reporting person signed the Form 4 on 10/02/2025.